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Abstract
The emergence of drug resistance in M. tuberculosis undermines the efficacy of tuberculosis (TB) treatment in individuals
and of TB control programs in populations. Multiple drug resistance is often attributed to sequential functional
monotherapy, and standard initial treatment regimens have therefore been designed to include simultaneous use of four
different antibiotics. Despite the widespread use of combination therapy, highly resistant M. tb strains have emerged in
many settings. Here we use a stochastic birth-death model to estimate the probability of the emergence of multidrug
resistance during the growth of a population of initially drug sensitive TB bacilli within an infected host. We find that the
probability of the emergence of resistance to the two principal anti-TB drugs before initiation of therapy ranges from 10
25
to 10
24; while rare, this is several orders of magnitude higher than previous estimates. This finding suggests that multidrug
resistant M. tb may not be an entirely ‘‘man-made’’ phenomenon and may help explain how highly drug resistant forms of
TB have independently emerged in many settings.
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Introduction
The World Health Organization estimates that there were
approximately 440,000 incident multidrug resistant tuberculosis
(MDR TB) cases in 2008. MDR TB is defined by resistance to
isoniazid (INH) and rifampin (RIF), the two most important
antitubercular antibiotics. The term extensively drug resistant
tuberculosis (XDR TB) describes MDR strains with additional
resistance to at least one agent in each of the two most effective
classes of second line drugs: a fluoroquinolone and an injectable
second-line drug (capreomycin, kanamycin, or amikacin). Over 50
countries have reported at least one case of XDR TB and several
report that more than 10% of MDR cases are also XDR [1,2].
XDR has been identified in different TB lineages and strains [3–
5], suggesting that it has emerged independently on multiple
occasions.
Drug resistance in TB is selected when individuals with active
tuberculosis are treated with drugs. Although an infectious ‘‘dose’’
of M. tuberculosis may consist of only a few bacilli that lodge in distal
alveoli of the lung, active pulmonary disease is not usually
clinically evident until the population of bacilli has reached a size
of 10
8–10
10 organisms [6,7]. Fluctuation tests demonstrate that
resistance to specific anti-tuberculosis drugs arises spontaneously at
a rate of one in 10
6–10
9 cell divisions, depending on the drug
[8,9]. Bacilli resistant to a single drug are therefore highly likely to
exist in any detectable TB lesion; accordingly, combination
therapy is a mainstay of current TB treatment regimens.
The rate of spontaneous occurrence of MDR TB – the
appearance of bacilli resistant to both isoniazid and rifampin before
therapy is initiated among those infected withdrug sensitive bacilli –
has not been measured directly. However, since the mutations that
confer resistance to isoniazid and rifampin are independent, it has
beenassumed that the rateofacquisitionofthisdual resistanceisthe
product of the two independent mutation rates, around 10
216
[10,11]. These calculations have often been interpreted to imply
that multidrug resistance is unlikely to arise spontaneously prior to
theadministrationofdrug therapy.Instead,the dominantparadigm
for how multidrug resistance arises invokes sequential monotherapy
leading to the progressive (stepwise) accumulation of resistance
mutations as follows. First, during the time a population of TB
bacilli grows from a small inoculum to a sufficient bacterial load to
trigger symptoms and diagnosis, mutations occur; a rare drug
resistant mutant may then be selected for during treatment.
Subsequently, as the drug sensitive population of bacteria dwindles,
the mutant population grows to high burden allowing the
occurrence of mutations to a second drug; ensuing exposure to
that drug now selects for doubly resistant bacilli. Since TB drugs are
now rarely administered alone, it is also assumed that exposure to a
single drugoccursthrough"functionalmonotherapy," i.e. treatment
that results in exposing M. tb bacilli to a single agent even when
multiple drugs are administered. Functional monotherapy may
occur when patients do not take their prescribed drugs regularly,
when they receive poor quality or counterfeit drugs, when drugs are
not properly absorbed through the GI tract or when bacteria grow
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either do not penetrate or where their activity is limited by pH or
some other functional constraint [7,12,13]. The idea that sequential
functional monotherapy is required for multidrug resistance to
emergehasledtothewidelyheld beliefthatmultidrug resistanceisa
"man-made phenomena" that results from poorly administered
therapy.
As others have noted, the calculation of the per replication
probability for the appearance of double mutants does not capture
the actual risk that multidrug resistance will emerge in a single
symptomatic infection prior to the administration of antibiotics
[7,14]. First, resistance to multiple antibiotics arises not only
during one replication event in which a single bacilli acquires two
independent mutations, but also can occur during the expansion of
a bacterial population from an inoculum even in the absence of
drug pressure. If mutations to single drugs occur early during the
within-host expansion of a population so that mono-resistant
bacilli constitute a major portion of the bacterial population at the
time of detection, the likelihood of mutation resulting in resistance
to a second drug during the subsequent growth of the population is
increased. The within-host emergence of bacilli resistant to
multiple drugs depends then not only on the probability of a
resistance mutation per replication and the selection pressure
provided by drug exposure, but also on the stochastic process that
governs the timing of the appearance of single mutants during the
growth of the population to a given size.
Secondly, previous estimates of the probability of spontaneous
multidrug resistance have also assumed that the population of M.
tb bacilli at detection size reflects the total number of replication
events the mycobacterial population has experienced. In contrast
to bacteria grown in culture, which do not experience natural
death, M. tb bacilli growing in an immunocompetent host are
frequently killed through adaptive or innate immune responses
and thus a host bacillary population of a given size is likely to have
undergone far more replication events than an in vitro population
of the same size.
Lastly, the potential fitness costs of resistance may also affect the
probability that resistance will be detected in a bacterial
population of a given size. Bacteria harboring resistance mutations
have been reported to grow more or less quickly than wild type
organisms [9,15]. Since the targets of anti-TB agents include
proteins and ribosomal components responsible for transcription,
translation and cell wall integrity, resistance mutations may be
expected to impede growth or increase the likelihood of cell death
in the context of an in vivo infection [16]. In the case of a fitness
cost of resistance, the sequential acquisition of multiple deleterious
resistance mutations should result in a cumulative fitness deficit
that may reduce the likelihood that a strain will evolve extensive
drug resistance.
Given these complexities, we developed a mathematical model
to estimate the probability that multidrug resistance would emerge
spontaneously during the growth of a population of M. tb from an
initial inoculum to a symptomatic TB infection, given known
mutations rates. Using a stochastic birth-death model of the
within-host emergence of drug resistant M. tb, we show that the
probability of emergence of MDR TB is much higher than
previously expected, even when combination chemotherapy is
reliably delivered.
Results
1) Emergence of monoresistance before treatment
We first model the emergence of mono-resistance to isoniazid in
an immunocompetent host infected by a single drug sensitive M. tb
bacillus. We assume that in this host, drug sensitive M. tb bacilli
replicate at a rate l,d i ea tr a t em and acquire INH resistance-
conferring mutations with probability b for each celldivision. Prior to
diagnosis, the population of sensitive cells grows at net rate l-m while
the population of resistant cells grows at rate l12m1=(l2m)Q,w h e r e
Q reflects the relative fitness of the resistant mutant. This putative
fitness cost can be incurred through reduced growth l1,l,i n c r e a s e d
death m1.m, or both. We assume the bacillary population grows until
it reaches size Nf, the size at which it is likely to produce symptoms
and cometo clinical diagnosis. The expected total number of resistant
bacilli at size Nf is the sum of the descendants of all INH resistant
mutants arising over the course of the clonal expansion of the
bacterial population. (See Supplement S1):
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Figure 1A showsthat for asetof parameters specific to the within-host
growth of M. tb (see Supplement S1), the number of resistant bacilli at
the time of detection varies with both the relative fitness of the
resistant mutants and with the net growth rate. The number of
mutants is higher when the net growth is lower because more cell
turnover has occurred at a given detection size, thereby creating more
replication events during which mutations could occur. In contrast to
previous estimates that there will be hundreds of INH resistant bacilli
present by the time an infection becomes symptomatic (i.e. reaches
size 10
10) [7,17,18,19], we estimate mean numbers of INH resistant
bacilli an order of magnitude higher.
Our results also demonstrate that the number of resistant
bacteria at the time of clinical detection is extremely variable
(Figure 1B). For example, in the biologically realistic scenario that
the fitness cost is less than 1/2, i.e. that Q.K, we find that the
distribution of mutant numbers has power-law tails with exponent
1/Q (see Supplement S1). This highly skewed distribution means
that some individuals have many times the average number (5000)
of INH-resistant mutants as illustrated in Figure 1.
2) Emergence of multidrug resistance before treatment
Using this model, we estimated the probability that multidrug
resistant cells arise prior to TB detection based on the expected
number of divisions of singly-resistant cells prior to the population
reaching size Nf. The probability that multiple resistance ever
emerges during the modeled growth of the singly-resistant
population is given by:
pdual~b12bNf
l
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This suggests that given known mutation rates, the probability
of a spontaneously occurring MDR TB bacillus pdual arising
during clonal expansion ranges from 1 in 3000 to 1 in 20,000,
and increases with relative fitness (Figure 2A). If we assume that
some of these bacilli will die prior to replication, the risk of dual
resistance at the time of detection is lower by a factor of
approximately ten (based on an extinction probability of
m1/l1).
Since recent evidence suggests that some isoniazid and rifampin
resistance mutations (such as the S315T mutation in katG) bear
little if any fitness cost [20,21,22,23], the probability that a second
resistance-conferring mutation will occur during the modeled
growth of an isoniazid resistant strain with this mutation may be as
high as 0.0005, or 1 in 2000. These numbers are in stark contrast
to previous estimates of the risk of dual resistance of approximately
Spontaneous Emergence of MDR Tuberculosis
PLoS ONE | www.plosone.org 2 March 2011 | Volume 6 | Issue 3 | e18327Figure 1. Distribution of INH-resistant mutants at the time of clinical detection of a TB patient. A Expected number of INH monoresistant
mutants at the time of detection, as a function of relative fitness and net growth rate. B The distribution of mutant numbers by relative fitness.
Horizontal red lines show the mean values in simulation, and the blue boxes illustrate the inter-quartile range. Small blue squares are the 5
th and 95
th
quantiles. The shaded blue region illustrates the 5
th–95
th quantile for the a-stable distribution.
doi:10.1371/journal.pone.0018327.g001
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[7,17,18,19].
3. Emergence of multidrug resistance during treatment
Dual resistance may also arise during combination therapy
while singly-resistant cells are killed through treatment. Although
four drugs are typically included in the first two months of
tuberculosis treatment, i.e. the initiation phase, only two drugs are
used during the subsequent continuation phase; consequently,
continuation therapy may efficiently select for dual resistance in
bacilli already resistant to one agent. Most active TB agents
including isoniazid, rifampin, streptomycin and fluoroquinolones
are bactericidal and for these, we assume that treatment increases
the death rate. Others such as ethambutol and PAS are
bacteriostatic and work through reducing the rate of bacillary
division. Although we assume that combination therapy will kill
both drug sensitive cells and singly-resistant mutants, continued
growth of at least some resistant mutants may occur during this
decline. This gives an estimated probability of dual-resistance
arising as:
ptr
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(See the Supplement S1 for a derivation).
Figure 2 shows that dual resistance may arise even during
completely effective treatment in as many as 1 in 10,000 cases
(p=3610
24) and could emerge either before or duringtreatment in
as many as 1 in 2500 cases (based on adding the probabilities in
Figure 2A and 2B). This is consistent with the fact that combination
therapy has been shown to be highly effective [7], but in settings in
which TB incidence is high, spontaneously-emerging multiple
resistance may account for occasional treatment failures.
The risk of emergence of multiple drug resistance is higher
when treatment increases the death rate than it is when treatment
reduces the division rate, even when the net rate of decline is the
same. This is because reducing the division rate reduces the
turnover of bacilli and thus the number of mutations. Further-
more, the probability of dual resistance emerging during
treatment is far greater when treatment is less rapidly bacteri-
cidal, reflecting the fact that more turnover may happen before
the population of single mutants is eliminated. This is consistent
with the observation that rifampin resistance is far more likely to
emerge from a population of isoniazid-resistant mutants than the
other way around [17], since the rapid bactericidal action of
isoniazid should suppress mutation among rifampin resistant
mutants but would not affect pre-existing isoniazid-resistant
mutants.
Discussion
Using a stochastic birth-death model of the within-host
emergence of drug resistance, we find that the probability that
Figure 2. Probability of dual resistance (pdual). Numbers are
based on b=2.25610
28 (isoniazid resistance) and b12=3.3610
29
(rifampin resistance) [7,8] A Before treatment begins, showing that
when mutants have higher relative fitness there is more mutant growth
corresponding to a higher probability that dual resistance will arise; B
After initiation of therapy; C After initiation of therapy, showing the
dependence on the net rate of decline. During the decline of the
bacterial population during therapy there may be some turnover,
although the death rate will be greater than the division rate. In
particular, if treatment increases the death rate but does not affect the
division rate there may be substantial turnover, resulting in a larger
probability that dual resistance may arise (green vs blue lines in panels
B and C). A more rapid net decline results in fewer births and a lower
risk of resistance. In each panel we allow the appearance of resistance
to isoniazid or rifampin to occur first, but the rapid bactericidal effect of
INH means that the net decline of INH-sensitive bacteria is much more
rapid than that of INH-resistant ones, and isoniazid resistance is thus
more likely to be observed before rifampin resistance in treated
patients. [19]
doi:10.1371/journal.pone.0018327.g002
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sensitive TB infection is orders of magnitude higher than
previously estimated. This result suggests that even in settings
where appropriate treatment is available and properly adminis-
tered, MDR tuberculosis can emerge during the within host
growth of the bacterial population. Since we model the idealized
scenario in which MDR bacilli arise from a completely sensitive
original infection, our results represent a lower bound on the
frequency of MDR; in a real world setting lapses in effective
chemotherapy and the transmission of resistant strains are also
major contributors to the burden of drug resistant TB. Although
we have here modeled the emergence of isoniazid mono-resistant
and MDR strains, TB mutates to develop resistance to other anti-
tuberculosis agents at rates that are similar or even higher than to
isoniazid [7,8] and therefore we expect that resistance to these
drugs also exists at high numbers in any advanced TB infection.
Furthermore, if mono-resistant strains are transmitted to a new
host and lead to secondary infections, our results predict that a
range of different dually resistant bacilli would arise, and
eventually be found in large numbers. Similarly, combination
therapy in patients with MDR would be expected to result in the
selection of dually resistant bacilli at high risk of developing further
resistance.
These results differ from previous expectations because we
allowed dual resistance to emerge during the expansion of a
population of TB bacilli in an immunocompetent host. This
formulation of the problem allowed us to consider the scenario in
which a second drug resistance mutation occurs during the growth
of a population of singly resistant mutants rather than assuming
that dual mutations occur during a single replication event. Zheng
has previously noted that classic estimates of the probability of the
occurrence of double mutants ignore the fact that sequential
random mutations are expected in a growing population of
bacteria[14].
We also assumed that in contrast to bacterial growth in vitro,
some pathogenic bacteria in an immunocompetent host will be
killed through an immune response and, thus, the number of
replication events required for a population to reach a given size is
greater than if death had not occurred [24]. Accordingly, since the
total number of replication events is lower in vitro, the risk of dual
resistance observed among bacteria grown in the laboratory may
not reflect the risks of dual resistance emerging in hosts.
High frequencies of mutation have been observed in isolates
from chronic clinical infection with other bacterial pathogens
including Stenotrophomonas maltophilia [25] and Pseudomonas aeruginosa
[26]. Furthermore, there is evidence that sub-lethal concentrations
of antibiotics can induce mutagenesis [27]. Our model does not
include this mechanism to account for the emergence of resistance,
largely because the evidence supporting hypermutability in M.
tuberculosis is mixed [28,29,30]. However, if M. tb bacilli do increase
their rate of mutation either during growth of the initial infection
or following exposure to antibiotics, we would expect the
emergence of multidrug resistance during treatment to be
accelerated and the overall frequency of the emergence of MDR
to be even higher than we have estimated here.
Our results may also underestimate the frequency of spontane-
ous resistance because we assume a fitness cost of the drug resistant
strain. Recent evidence suggests that the initial fitness costs of some
drug resistance mutations can be rapidly compensated by
secondary mutations that restore normal function [31,32,33]. In
this case, fitness costs may be transient and the probability of the
emergence of resistance will thus be at the upper end of the
spectrum presented here. Interestingly, the acquisition of a fitness-
restoring mutation in a singly resistant mutant during clonal
expansion of the TB population should follow very similar
dynamics to those we have presented here for dual resistance.
On the other hand, if only a fraction of mutations observed during
in vitro growth of M. tuberculosis are actually found in clinical
strains [34], the mutation rates cited in this study are higher than
those that would reflect the acquisition of clinical resistance. In this
case, both the standard approach and our model would predict
correspondingly lower risk of emergence of multiple resistance, but
our estimates would still be orders of magnitude higher.
In summary, using a simple model of an initially drug sensitive
M. tb infection, we estimated that the probability that MDR exists
at the time of diagnosis may be 1000–10,000 times higher than
previously suggested. Based on these results, we anticipate that
dually resistant strains will be present in a small minority of
patients even prior to treatment, and, for this subset of patients,
standard drug regimens administered properly will likely result in
the selection of pre-existing dual resistance. Our results point to a
mechanism, distinct from functional monotherapy, which can
explain how highly drug resistant M. tb may emerge in the context
of combination therapy. We propose that this may account for the
repeated independent emergence of MDR and by extension,
XDR tuberculosis, both in individuals and across a wide range of
geographical settings.
Methods
We model infection arising as a result of infection with one drug
sensitive bacillus. This bacillus divides and at each division may
create a resistant mutant with probability b, which for isoniazid
resistance is on the order of 10
28 [8]. In a clinical TB infection
there may be up to 10
10 bacilli [9], so we expect that several
mutation events will have occurred. We wish to find the
distribution of the total number of mutants, including descendants
of early mutation events. This problem is closely related to the
Luria-Delbruck theory [35,36,37] and subsequent mathematical
models [38,39,40,41,42]; however, these typically either do not
include cell death or assume that resistant mutants divide and die
at the same rates as sensitive cells [22,24,36]. Furthermore, we
develop an intuitive approach to the distributional estimate,
avoiding the use of generating functions. This approach is
particularly useful in the description of within host TB dynamics,
as TB infections are large enough that the population of single
mutants is expected to be substantial and therefore a focus on the
probability of single resistance is less relevant than in related work
on the emergence of resistance in cancer [43]. We assume that
there is a fitness cost associated with drug resistance, i.e., that the
relative fitness of the mutant compared to the sensitive strain is
smaller than 1 (though it may be close to 1 if the fitness cost is low).
Combined with the rarity of mutations, this ensures that mutants
will comprise only a very small proportion of the population, so
that the time when sensitive cells reach the detection size is very
close to the time that the entire population reaches that size[44]
Also, drug sensitivity testing would be very unlikely to detect
resistant mutants under these assumptions.
Mean mutant numbers
We compute the mean single mutant numbers as a function of
the relative fitness and growth and death rates of the sensitive cells
by finding the mean growth of the sensitive cell population
between any two mutation events. We then relate the net growth
of mutant cells to the net growth of sensitive cells via the relative
fitness (see Supplement S1); the mean mutant population at the
time of detection is the sum of the descendants of all of the mutants
that arose during the growth of the sensitive population.
Spontaneous Emergence of MDR Tuberculosis
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We find the distributional estimate for the total mutant number
at the time of detection essentially by showing that mutations
occur uniformly over the growth of the sensitive population. We
then show that the number of descendants of an individual mutant
is a random variable Q which has a Pareto distribution, whose
complementary cumulative distribution behaves like x
1/Q; this
gives rise to the infinite-variance distributions for Q.K. The total
mutant population is composed of a sum of J i.i.d quantities
distributed as Q, and J itself is Poisson. This, together with the fact
that the sensitive cell population at the time of detection is large
enough that many different mutants have arisen, means that the
mutant numbers at the time of detection are approximated by an
a-stable distribution. See the Supplement S1 for the details of this
derivation.
Dual mutants
Both before and after treatment begins, we compute the
probability that a dually resistant mutant arises by finding the
expected number of arrivals or divisions of singly resistant mutant
cells. Each time a singly resistant cell is created there is a small
probability that it is dually resistant, and this combined with the
results on mean mutant numbers yields the expression above for
the probability of dual resistance. Further details are presented in
the Supplement S1.
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